Get started
Author

Andrea Rodríguez‐Lopez

Impact of CYP2C:TG Haplotype on CYP2C19 Substrates Clearance In Vivo, Protein Content, and In Vitro Activity
2023 · Pablo Zubiaur, Paula Soria‐Chacartegui, et al. · Clinical Pharmacology & Therapeutics · 15
PDF
Evaluation of the role of metabolizing enzymes and transporter variants in ezetimibe pharmacokinetics
2024 · Eva González-Iglesias, Dolores Ochoa, et al. · Frontiers in Pharmacology · 6
Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers
2024 · Andrea Rodríguez-Lopez, María Martínez-Sendino, et al. · Biomedicines · 5
PDF
Effect of Genetic Variants on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Involvement of ABCG2, SLCO1B1 and NAT2
2024 · Eva González-Iglesias, Clara Méndez-Ponce, et al. · International Journal of Molecular Sciences · 4
PDF
Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Finasteride
2023 · Gonzalo Villapalos-García, Pablo Zubiaur, et al. · Journal of Personalized Medicine · 4
PDF
Impact of Sex and Genetic Variation in Relevant Pharmacogenes on the Pharmacokinetics and Safety of Valsartan, Olmesartan and Hydrochlorothiazide
2023 · Paula Soria-Chacartegui, Pablo Zubiaur, et al. · International Journal of Molecular Sciences · 4
PDF
Genetic Variation in CYP2D6, UGT1A4, SLC6A2 and SLCO1B1 Alters the Pharmacokinetics and Safety of Mirabegron
2024 · Paula Soria-Chacartegui, Patricia Cendoya-Ramiro, et al. · Pharmaceutics · 2
Genetic variation in UGT1A1 is not associated with altered liver biochemical parameters in healthy volunteers participating in bioequivalence trials
2024 · Eva González-Iglesias, Dolores Ochoa, et al. · Frontiers in Pharmacology · 2
PDF
An Investigational Study on the Role of CYP2D6, CYP3A4 and UGTs Genetic Variation on Fesoterodine Pharmacokinetics in Young Healthy Volunteers
2024 · Andrea Rodríguez-Lopez, Dolores Ochoa, et al. · Pharmaceuticals · 1
PDF
SLCO1B1 and ABCG2 genotype‐informed phenotypes are related to variation in ramipril exposure
2024 · Houwaida Abbes, Pablo Zubiaur, et al. · Basic & Clinical Pharmacology & Toxicology · 1
Use of Exposure Data to Establish Causality in Drug–Adverse Event Relationships: An Example with Desvenlafaxine
2024 · Andrea Rodríguez-Lopez, Gina Mejía-Abril, et al. · Pharmaceuticals · 1
PDF
Design of an Array to Evaluate Biomarkers of Response to Biological Treatments in Inflammatory Bowel Disease
2025 · Andrea Rodríguez-Lopez, Eva González-Iglesias, et al. · Future Pharmacology
PDF
Works count: 12
Citation count: 45
H-index: 4
I10-index: 1
Year
Topic
Type